Receptors, Antigen
- Name
- Receptors, Antigen
- Accession Number
- DBCAT004651
- Description
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
- Drugs
Drug Drug Description Tisagenlecleucel A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. Idecabtagene vicleucel An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. - Drugs & Drug Targets
Drug Target Type Tisagenlecleucel B-lymphocyte antigen CD19 target Brexucabtagene autoleucel B-lymphocyte antigen CD19 target Idecabtagene vicleucel Tumor necrosis factor receptor superfamily member 17 target